Antibodies for bioanalysis and drug monitoring of infliximab and biosimilars

Develop highly selective and sensitive PK and ADA assays for infliximab (Remicade) using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory and non-inhibitory antibodies specific to infliximab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Infliximab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Infliximab Inhibitory Type 1

HCA212

AbD17837

Fab-V5Sx21

0.9

PK bridging ELISA

Order HCA212

HCA213
HCA213P

AbD17841_hIgG1

hIgG1

HRP

1.8

PK bridging ELISA

ADA control

Order HCA213
Order HCA213P

HCA233

AbD20436_hIgG1

hIgG1

0.12

PK bridging ELISA

ADA control

Order HCA233

HCA234

AbD20436

Fab-FH2

0.12

PK bridging ELISA

Order HCA234

Infliximab & Infliximab-TNFα

Non-Inhibitory

Type 2

HCA214

AbD19376

Fab-FH2

0.7

PK bridging ELISA

Order HCA214

HCA215

AbD19370_hIgG1              

hIgG1

1.4

PK bridging ELISA

Order HCA215

HCA216
HCA216P

AbD19376_hIgG1

hIgG1

HRP

0.7

PK bridging ELISA

Order HCA216
Order HCA216P

* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody, V5- and StrepX-StrepX- tags

2 Monovalent Fab antibody DYKDDDDK- and His-6-tags


Anti-Infliximab Inhibitory Antibodies (Type 1)

Type 1 anti-infliximab antibodies inhibit the binding of the drug infliximab to its target, tumor necrosis factor alpha, TNFα. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.


Anti-Infliximab Non-Inhibitory Antibodies (Type 2)

Type 2 anti-infliximab antibodies bind to the infliximab idiotope, but do not inhibit the binding of infliximab to TNFα. They are ideal for development of a PK bridging ELISA to measure total drug - free, partially bound and fully bound.


ELISA Protocols to Get You Started

PK Bridging ELISAs


PK bridging ELISA using antibodies HCA212 and HCA213

Fig. 1. Infliximab PK bridging ELISA using antibodies HCA212 and HCA213P.

Pharmacokinetic (PK) Assay

Schematic image of PK bridging ELISA detecting free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.



Fig. 2. Infliximab PK ELISA bridging format using antibodies HCA214 and HCA216P.

Fig. 2. Infliximab PK ELISA bridging format using antibodies HCA214 and HCA216P.

Schematic image of PK bridging ELISA detecting total drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.


ADA Bridging ELISA


Fig. 3. ADA bridging ELISA using antibody HCA213.

Anti-Drug Antibody Assay

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue)


Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.